Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-r4mrb Total loading time: 0 Render date: 2025-03-09T02:34:00.891Z Has data issue: false hasContentIssue false

Amantadine

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Amantadine (tricyclo[3.3.1.1]decan-1-amine, 1-adamantanamine, 1-aminoadamantane) is a white or nearly white crystalline, odourless, and bitter-tasting powder, with a molecular weight of 151.25 and an empirical formula of C10H17N. Amantadine is a tricyclic amine with two available preparations, amantadine hydrochloride, which is given orally, and the salt amantadine sulphate, which is administered either orally or IV.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 2 - 15
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Isaacson, SH, Fahn, S, Pahwa, R, Tanner, CM, Espay, AJ, Trenkwalder, C, Adler, CH, Patni, R, Johnson, R. Parkinson’s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Dis Clin Pract 2018; 5(2): 183–190.CrossRefGoogle ScholarPubMed
Marmol, S, Feldman, M, Singer, C, Margolesky, J. Amantadine revisited: a contender for initial treatment in Parkinson’s disease? CNS Drugs 2021; 35(11): 1141–1152.CrossRefGoogle ScholarPubMed
Rascol, O, Fabbri, M, Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol 2021; 20(12): 1048–1056.CrossRefGoogle ScholarPubMed
Thomas, A, Bonanni, L, Gambi, F, Di Iorio, A, Onofrj, M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68(3): 400–404.CrossRefGoogle Scholar

References

Aarsland, D, Batzu, L, Halliday, GM, Geurtsen, GJ, Ballard, C, Ray Chaudhuri, K, Weintraub, D. Parkinson disease-associated cognitive impairment. Nature Rev Dis Primers 2021; 7(1): 47.CrossRefGoogle ScholarPubMed
AHFS Drug information. Bethesda: American Society of Health-System Pharmacists (2012). Accessed via www.medicinescomplete.com on 29 December 2022.Google Scholar
Amantadine. In: Brayfield, A (Ed), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed online via www.medicinescomplete.com on 31 October 2021.Google Scholar
Amantadine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed via www.micromedexsolutions.com on 31 October 2021.Google Scholar
Chang, C, Ramphul, K. Amantadine. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2022, StatPearls Publishing LLC; 2022.Google Scholar
da Silva-Júnior, FP, Braga-Neto, P, Sueli Monte, F, de Bruin, VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005; 11(7): 449–452.CrossRefGoogle ScholarPubMed
Giladi, N, Treves, TA, Simon, ES, Shabtai, H, Orlov, Y, Kandinov, B, Paleacu, D, Korczyn, AD. Freezing of gait in patients with advanced Parkinson’s disease. J Neural Transm (Vienna) 2001; 108(1): 53–61.CrossRefGoogle ScholarPubMed
Isaacson, SH, Fahn, S, Pahwa, R, Tanner, CM, Espay, AJ, Trenkwalder, C, Adler, CH, Patni, R, Johnson, R Parkinson’s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract 2018; 5(2): 183–190.CrossRefGoogle Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed via www.medicinescomplete.com on 29 December 2022.Google Scholar
Lechin, F, van der Dijs, B, Pardey-Maldonado, B, Rivera, JE, Baez, S, Lechin, ME. Effects of amantadine on circulating neurotransmitters in healthy subjects. J Neural Transm (Vienna) 2010; 117(3): 293–299.CrossRefGoogle ScholarPubMed
Malkani, RC Zadikoff, O Melen, A Videnovic, E Borushko, T Simuni, . Amantadine for freezing of gait in patients with Parkinson disease. Clin Neuropharmacol 2012; 35(6): 266–268.CrossRefGoogle ScholarPubMed
Metman, LV, Del Dotto, P, LePoole, K, Konitsiotis, S, Fang, J, Chase, TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56(11): 1383–1386.CrossRefGoogle ScholarPubMed
Moresco, RM, Volonte, MA, Messa, C, et al. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET–[(11)C]raclopride study. J Neural Transm (Vienna) 2002; 109(10): 1265–1274.CrossRefGoogle Scholar
Oertel, WK Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, JP Azulay, S Isaacson, L Felt, MJ Stempien, . Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord 2017; 32(12): 1701–1709.CrossRefGoogle ScholarPubMed
Ory-Magne, F, Corvol, JC, Azulay, JP, Bonnet, AM, Brefel-Courbon, C, Damier, P, Dellapina, E, Destée, A, Durif, F, Galitzky, M, Lebouvier, T, Meissner, W, Thalamas, C, Tison, F, Salis, A, Sommet, A, Viallet, F, Vidailhet, M, Rascol, O. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014; 82(4): 300–307.CrossRefGoogle ScholarPubMed
Ossola, B, Schendzielorz, N, Chen, SH, Bird, GS, Tuominen, RK, Männistö, PT, Hong, JS. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 2011; 61(4): 574–582.CrossRefGoogle ScholarPubMed
Pahwa, R, Tanner, CM, Hauser, RA, Isaacson, SH, Nausieda, PA, Truong, DD, Agarwal, P, Hull, KL, Lyons, KE, Johnson, R, Stempien, MJ. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol 2017; 74(8): 941–949.CrossRefGoogle ScholarPubMed
Rascol, O, Fabbri, M, Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol 2021; 20(12): 1048–1056.CrossRefGoogle ScholarPubMed
Rascol, O, Tönges, L, deVries, T, Jaros, M, Quartel, A, Jacobs, D. Immediate-release/extended-release amantadine (OS320) to treat Parkinson’s disease with levodopa-induced dyskinesia: analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord 2022; 96: 65–73.CrossRefGoogle ScholarPubMed
Sanders, WL. Creutzfeldt–Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry 1979; 42(10): 960–961.CrossRefGoogle ScholarPubMed
Sawada, H, Oeda, T, Kuno, S, Nomoto, M, Yamamoto, K, Yamamoto, M, Hisanaga, K, Kawamura, T. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 2010; 5(12): e15298.CrossRefGoogle ScholarPubMed
Snow, BJ, Macdonald, L, McAuley, D, Wallis, W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23(2): 82–85.CrossRefGoogle ScholarPubMed
Sommerauer, C, Rebernik, P, Reither, H, Nanoff, C, Pifl, C. The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology 2012; 62(4): 1708–1716.CrossRefGoogle ScholarPubMed
Summary of Product Characteristics – Amantadine hydrochloride 100 mg capsules. Electronic Medicines Compendium: Amantadine hydrochloride 100 mg capsules – summary of product characteristics (SmPC) – (emc). Accessed on 31 October 2021 via www.medicines.org.uk.Google Scholar
Tanner, CM, Pahwa, R, Hauser, RA, Oertel, WH, Isaacson, SH, Jankovic, J, Johnson, R, Chernick, D, Hubble, J. EASE LID 2: a 2-year open-label trial of Gocovri (amantadine) extended release for dyskinesia in Parkinson’s Disease. J Parkinsons Dis 2020; 10(2): 543–558.CrossRefGoogle ScholarPubMed
Thomas, A, Bonanni, L, Gambi, F, Di Iorio, A, Onofrj, M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68(3): 400–404.CrossRefGoogle ScholarPubMed
Verhagen Metman, L, Del Dotto, P, van den Munckhof, P, Fang, J, Mouradian, MM, Chase, T. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998; 50(5): 1323–1326.CrossRefGoogle ScholarPubMed
Weintraub, D, Sohr, M, Potenza, MN, Siderowf, AD, Stacy, M, Voon, V, Whetteckey, J, Wunderlich, GR, Lang, AE. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010; 68(6): 963–968.CrossRefGoogle ScholarPubMed
Wolf, E, Seppi, K, Katzenschlager, R, Hochschorner, G, Ransmayr, G, Schwingenschuh, P, Ott, E, Kloiber, I, Haubenberger, D, Auff, E, Poewe, W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 2010; 25(10): 1357–1363.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Amantadine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.003
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Amantadine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.003
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Amantadine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.003
Available formats
×